Registry Data Reported for Best-Practice Impella Heart Pump Support in High-Risk PCI 

November 4, 2026—Johnson & Johnson MedTech announced results from three clinical analyses that report survival and patient outcomes data when the company’s Impella heart pumps are used to support a patient’s heart during and after high-risk percutaneous coronary intervention (HRPCI).

Study Reports Low Operator Radiation Exposure With Rampart Guardian System

November 4, 2026—An observational study evaluating operator radiation exposure during endovascular procedures with the Rampart Guardian shielding system was presented at TCT 2026 and simultaneously published in JSCAI.

Anteris Reports 30-Day DurAVR THV Data From EMBARK

November 4, 2026—Anteris Technologies announced 30-day clinical and hemodynamic outcomes for its medium-size DurAVR transcatheter heart valve (THV) in 22 patients with severe aortic stenosis and medium aortic annuli enrolled in the EMBARK study.

FIH Results Reported for Robocath’s Next-Generation Robotic System for PCI

November 4, 2026—Stereotaxis announced first-in-human (FIH) results from a prospective pilot study evaluating Robocath’s next-generation robotic system for percutaneous coronary intervention (PCI).

SPIRARE II Post Hoc Analyses Presented for Jupiter Endovascular’s Vertex Thrombectomy System

November 3, 2026—Jupiter Endovascular, Inc., announced findings from post hoc analyses of its SPIRARE II pivotal trial examining pulmonary artery (PA) pressure and right ventricular (RV) recovery after treatment with the company’s Vertex thrombectomy system for pulmonary embolism (PE).

Primary Endpoint Results Presented From Medtronic’s SPYRAL AFFIRM Postapproval RDN Study

November 3, 2026—Medtronic announced that the SPYRAL AFFIRM postapproval study of its Symplicity Spyral renal denervation (RDN) system met its primary endpoint, demonstrating statistically significant reductions in office, home, and 24-hour ambulatory systolic blood pressure at 6 months in patients with uncontrolled hypertension.

Philips Announces United States Launch of HyperVue Integrated System

November 3, 2026—Royal Philips announced the United States commercial availability of its HyperVue Integrated system, a fixed, single-room configuration of its HyperVue imaging system that combines DeepOCT+NIRS (optical coherence tomography and near-infrared spectroscopy) intravascular imaging with X1-FFR (fractional flow reserve) coronary physiology assessment.

The PERT Consortium Names Mark McIlduff as Executive Director

November 3, 2026—The PERT Consortium announced the appointment of Mark McIlduff as Executive Director.